|
President Donald Trump on Monday announced nine more deals with pharmaceutical companies to lower certain drug prices, the latest addition to his administration’s effort to address health care affordability. The most-favored-nation deals generally aim to compel companies to launch new medicines in the United States at prices similar to those charged in other wealthy nations and offer lower prices for many current drugs to state Medicaid programs, which provide health coverage for millions of low-income Americans.
The nine new drugmakers are Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals and UCB. To date, 26 pharmaceutical companies have now announced deals with the Trump administration to lower their prices and bring more drug manufacturing to the U.S. In exchange, many of the companies are exempt from potential future tariffs.
|